Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02445131
Recruitment Status : Recruiting
First Posted : May 15, 2015
Last Update Posted : June 25, 2018
Sponsor:
Collaborators:
Hoffmann-La Roche
Gilead Sciences
Information provided by (Responsible Party):
German CLL Study Group

Brief Summary:
The CLL2-BCG-trial is a prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of a debulking with bendamustine followed by an induction with GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101-maintenance in CLL patients

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leucemia Drug: Bendamustine Drug: GA101 Drug: CAL-101 Phase 2

Detailed Description:
In the CLL2-BCG-trial, a total of 62 patients of an allcomer CLL population (irrespective of physical fitness, previous therapies and prognostic factors) with an indication for treatment will be included. Patients will receive 2 cycles of debulking treatment with bendamustine unless contraindications (e.g. refractoriness) are present or a debulking is not indicated due to a low tumor burden. Afterwards, 6 cycles of induction treatment with GA101 (obinutuzumab, 3 doses in the first cycle and monthly in cycles 2-6) and CAL-101 (idelalisib, continuously starting in cycle 2) will be applied. The primary endpoint overall response rate will be assessed at final restaging (2 months after end of induction treatment). Patients benefitting from treatment receive further therapy with GA101 (3 monthly) and CAL-101 (continuously) in a maintenance phase for up to 24 months. Maintenance treatment will be stopped in case of achievement of a complete remission and confirmation of MRD (minimal residual disease) negativity in peripheral blood or if unacceptable toxicity or progression occurs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 62 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Open-label, Multicenter Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 (Obinutuzumab) and CAL-101 (Idelalisib) Followed by CAL-101 and GA101 Maintenance in CLL Patients
Actual Study Start Date : May 27, 2015
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : May 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Bendamustine + GA101 + CAL-101
Bendamustine: 70 mg/m2 i.v. GA101: 1000 mg CAL-101: 150 mg p.o.
Drug: Bendamustine
Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.

Drug: GA101

Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 & 15: 1000mg; Cycle 2-6: d1: 1000mg

Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg.

Other Name: Obinutuzumab

Drug: CAL-101

Induction: Cycle 2-6: d1-28: 150 mg p.o.

Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o.

Other Name: Idelalisib




Primary Outcome Measures :
  1. Overall response rate (ORR) [ Time Frame: 84 days after start of the last induction cycle ]
    Proportion of patients responding according to international working Group on chronic lymphocytic leukemia criteria


Secondary Outcome Measures :
  1. Adverse Events (AEs) and adverse events of special interest (AESI) [ Time Frame: up to 40 months after first dose of study drug ]
    Type, frequency and severity of adverse events (AEs) and adverse events of special interest (AESI) and their relationship to study treatment

  2. Rate of minimal residual disease (MRD) [ Time Frame: up to 40 months ]
    Rate of MRD responses in peripheral blood measured by immunophenotyping



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • documented chronic lymphocytic leukemia (CLL) requiring treatment according to International Working Group on CLL (iwCLL) criteria
  • adequate hematologic function: platelets ≥ 25.000/µl, neutrophils ≥ 1.000/µl and hemoglobin ≥8.0 g/dL, unless directly attributable to the patient´s CLL (e.g. bone marrow infiltration)
  • adequate renal function: a creatinine clearance ≥30ml/min calculated according to the modified formula of Cockcroft and Gault or directly measured with 24 hr. urine collection
  • adequate liver function: total bilirubin ≤1,5x, aspartate aminotransferase (AST) / alanin aminotransferase (ALT) ≤2.5x the institutional upper limit of normal (ULN) value, unless directly attributable to the patient's CLL or to Gilbert's Syndrome
  • negative serological testing for hepatitis B, negative testing for hepatitis-C RNA and negative HIV test within 6 weeks prior to registration
  • age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2, ECOG 3 is only permitted if related to CLL
  • life expectancy ≥ 6 months
  • ability and willingness to provide written informed consent and to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

  • transformation of CLL (i.e. Richter's transformation, prolymphocytic leukemia)
  • known central nervous system (CNS) involvement
  • confirmed progressive multifocal leukoencephalopathy (PML)
  • malignancies other than CLL currently requiring systemic therapies
  • uncontrolled infection requiring systemic treatment
  • any comorbidity or organ system impairment rated with a cumulative illness rating scale (CIRS) score of 4, excluding the eyes/ears/nose/throat/larynx organ system or any other life-threatening illness, medical condition or organ system dysfunction that - in the investigator´s opinion - could compromise the patients safety or interfere with the absorption or metabolism of the study drugs (e.g, inability to swallow tablets or impaired resorption in the gastrointestinal tract)
  • ongoing inflammatory bowel disease
  • ongoing drug induced pneumonitis
  • use of investigational agents which would interfere with the study drug ≤28 days prior to registration
  • known hypersensitivity to GA101 (obinutuzumab), CAL-101 (idelalisib) or any of the excipients
  • pregnant women and nursing mothers
  • fertile men or women of childbearing potential unless surgically sterile or ≥ 2 years after the onset of menopause, or willing to use two methods of reliable contraception including one highly effective (Pearl Index <1) and one additional effective (barrier) method during study treatment and for 18 months after end of study treatment
  • vaccination with a live vaccine ≤28 days prior to registration
  • legal incapacity
  • prisoners or subjects who are institutionalized by regulatory or court order
  • persons who are in dependence to the sponsor or an investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02445131


Contacts
Layout table for location contacts
Contact: Paula Cramer, Dr. med. 0221 478 88220 paula.cramer@uk-koeln.de
Contact: Julia von Tresckow, Dr. med. 0221 478 88220 julia.von-tresckow@uk-koeln.de

Locations
Layout table for location information
Germany
German CLL Study Group Recruiting
Cologne, Germany, 50935
Contact: Paula Cramer, Dr. med.    0221 478 88220    paula.cramer@uk-koeln.de   
Contact: Julia von Tresckow, Dr. med.    0221 478 88220    julia.von-tresckow@uk-koeln.de   
Sponsors and Collaborators
German CLL Study Group
Hoffmann-La Roche
Gilead Sciences
Investigators
Layout table for investigator information
Principal Investigator: Paula Cramer, Dr. med. German CLL Study Group

Additional Information:
Layout table for additonal information
Responsible Party: German CLL Study Group
ClinicalTrials.gov Identifier: NCT02445131     History of Changes
Other Study ID Numbers: CLL2-BCG
2014-000582-47 ( EudraCT Number )
First Posted: May 15, 2015    Key Record Dates
Last Update Posted: June 25, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by German CLL Study Group:
CLL

Additional relevant MeSH terms:
Layout table for MeSH terms
Bendamustine Hydrochloride
Obinutuzumab
Idelalisib
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Immunological
Enzyme Inhibitors